Recursion to Participate in Upcoming Investor Conferences
May 02, 2023 08:30 ET
|
Recursion Pharmaceuticals
Salt Lake City, May 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its...
Recursion to Participate in Upcoming Investor Conference
April 03, 2023 08:30 ET
|
Recursion Pharmaceuticals
Salt Lake City, April 03, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced...
Recursion Publishes Second Annual Environmental, Social and Governance Report
March 28, 2023 16:14 ET
|
Recursion Pharmaceuticals
Salt Lake City, March 28, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced...
Recursion to Participate in Upcoming Investor Conferences
March 01, 2023 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced...
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results
February 27, 2023 16:30 ET
|
Recursion Pharmaceuticals
Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clinical data readoutsDelivered against core elements of our Roche-Genentech...
Community Leaders Unite to Provide Support and Resources for Thousands of Utahns with Rare Diseases
February 21, 2023 11:00 ET
|
Recursion Pharmaceuticals
Salt Lake City, Utah, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rare Disease advocacy organizations and biotech and healthcare industry leaders will partner to accelerate the diagnosis and improve the care...